About us
Bringing our expertise in healthcare to support your development
Vivalto Partners is an independent management company approved by the Autorité des Marchés Financiers (“AMF”), specialized in healthcare investments. We invest in small and mid-sized profitable companies and team-up with their management teams to assist them in their development, bringing capital in addition to a strategic and operational assistance.
Founded in 2021 by Daniel Caille, who pioneered the private hospital space in France, Vivalto Partners brings together healthcare experts and investment professionals with an ambition to support companies working towards a better quality of care to address the great challenges of the healthcare sector transformation in Europe.
An investment company solely dedicated to healthcare
Healthcare expenditures in Europe have been growing steadily for several decades. With little correlation to economic cycles, their evolution is linked to an ageing population, the growing prevalence of chronic diseases, increasing sensitivity to the theme of well-being and the development of innovations. The European healthcare market is resilient, protected by high barriers to entry linked to regulation, technology, reputation and investment requirements.
There are around 5,000 large independent SMEs and small ETIs in Western Europe, most of which were founded in the 1980s and 1990s. Vivalto Partners can offer solutions to these challenges, which include buyouts, external growth financing, internationalization and investment in innovation.
Investment strategy
When selecting new investments and supporting portfolio companies on operations, financing, M&A and other selected topics, Vivalto Partners relies on the combined experience of its investment team, a broad set of exclusive experts and Key Opinion Leaders (KOLs) from its network, in addition to Senior Advisors with highly relevant experiences in leading companies within their respective healthcare verticals.
Our sectors of interest
Vivalto Partners backs growing and profitable companies in France and continental Europe and prioritarily targets 4 selected verticals:
PATIENT SERVICES
Building consolidation platforms, assisting on international expansion, integrating state-of-the-art technologies to improve quality of care, improving accessibility of care and better meeting patients’ needs whilst best managing costs for payors
PHARMA AND CONSUMER HEALTHCARE
Leveraging large pharma groups’ outsourcing dynamic as well as the wellbeing and alternative care trends to invest in profitable and high-growth potential products
MEDICAL DEVICES
Supporting the emergence of product / niche / geographical leaders by fueling their production capacity increase, product innovation, geographical expansion, product diversification, amidst a growing European market where regulation becomes steadily harmonized
B2B SERVICES
Supporting healthcare clients focus on their core business to unlock productivity gains (outsourcing of complex or non-core processes) and contribute to the improvement of care (patient pathway, diagnosis, training and staffing of caregivers, healthcare data management, etc.
ESG
The fund is actively involved on ESG topics and champions a responsible approach to value creation. Our investment process systematically accounts for all main aspects of ESG. The management company is a member of the France Invest association and will be signatory of the UN Principles for Responsible Investment. The fund currently being deployed – Vivalto Capital 1 – will be meeting the requirements of the article 8 of the Disclosure Regulation or SFDR adopted by the European Parliament and the Council of the European Union on November 27th 2019.